Individuals Discontinuing Weight-Loss Medications Gain Back Weight at a Quadrupled Rate Than Dieters

New research suggests that individuals who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who halt conventional diet and exercise regimens.

Findings released in a prominent health publication demonstrates that while obese people can lose about a fifth of their body weight while on the medication, the mass is regained at an average rate of nearly a kilo each month after stopping.

"People buying these treatments need to be informed of the risk of fast rebound weight gain when the medication is stopped," warns expert Dr. Susan Jebb.

This pace of regain means a return to pre-treatment weight in about a year and a half.

Weighing Therapies

The study, which examined 37 of trials involving over 9,000 of patients, compared the effects of the injectable medications with older methods.

The team emphasize that individuals who shed pounds through dieting usually have a less rapid weight regain—around 0.1 kg a month—once they finish.

The Reason for the Fast Rebound

Doctors propose the mechanism of the drugs is key to understanding the heightened rebound.

These medications copy a natural hormone called GLP-1, which controls feelings of fullness.

"Sustained high doses of GLP-1 levels several times higher than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and could reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.

"Stopping of this medication leads to hunger is no longer kept in check, making binge eating a significant risk."

An Ongoing Condition?

Medical guidelines recommend the injections for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.

Professionals argue that, due to the likelihood of weight regain, the treatment should be considered ongoing.

This opinion is reinforced by pharmaceutical companies, who note that the results "emphasize the long-term character of excess weight," similar to managing diseases like diabetes.

Patient Accounts

People who have discontinued the jabs explain a powerful resurgence of appetite.

"It felt as if a switch flipping and I was suddenly starving," said an individual.

This challenge is compounded if users have not developed permanent dietary or behavioural modifications during treatment.

Widespread Adoption

Figures suggest that millions of adults in the UK have used weight-loss jabs in the past year, with desire being substantial.

• Use is higher among females than males.
• The middle-aged demographic shows the highest level of interest.
• A large proportion obtain the medications through private prescriptions rather than public health services.

Ultimately, clinicians emphasize that while the jabs are powerful agents for shedding pounds, they are not a standalone solution and maintained weight loss likely depends on integrated behavioural support.